Palvella Therapeutics’ Phase 3 SELVA Trial Shows >2-Point Improvement, Fuels 43% Stock Surge
Palvella’s Phase 3 SELVA trial of QTORIN gel in 49 patients achieved a mean >2-point improvement on the Investigator Global Assessment with no drug-related serious adverse events and nearly all participants entering extension. It plans an NDA in H2 2026 targeting U.S. approval by mid-2027 for the 30,000-patient disease.
1. Phase 3 SELVA Trial Success
The SELVA study enrolled 49 patients aged six and older with microcystic lymphatic malformations and met its primary endpoint on the Investigator Global Assessment, delivering a mean improvement of over two points. Nearly all eligible participants opted into the extension phase, and no drug-related serious adverse events were reported.
2. First Potential FDA-Approved Therapy
QTORIN 3.9% rapamycin gel targets a rare, progressive vascular malformation affecting approximately 30,000 U.S. patients, a condition with no current FDA-approved therapies. The topical formulation demonstrated low systemic exposure and a favorable safety profile in both pediatric and adult populations.
3. Regulatory Filing Timeline
Based on the positive topline results, Palvella plans to submit a New Drug Application to the FDA in the second half of 2026, aiming for potential U.S. approval in the first half of 2027. This timeline positions QTORIN for market entry ahead of competing mTOR inhibitors.
4. Expansion of QTORIN Franchise
Beyond microcystic lymphatic malformations, the company is advancing QTORIN rapamycin in additional mTOR-driven skin and vascular disorders. Ongoing trials aim to broaden the drug’s addressable market and support long-term revenue growth if further studies replicate SELVA’s success.